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Akute myeloische Leukämie · Gemtuzumab Ozogamicin
Zusammenfassung
Der Stellenwert von Gemtuzumab Ozogamicin (GO) in
der Kombination mit Chemotherapie für die Behandlung
der akuten myeloischen Leukämie (AML) wird derzeit
auch in Europa untersucht. Der Einsatz von GO (6
mg/m2) in Kombination mit Cytarabin (100 mg/m2) bei
der Primärbehandlung älterer Patienten mit AML wird in
der SAL-Phase-II-Studie geprüft. Das in der MRC-AML15-
Studie nachgewiesene verbesserte krankheitsfreie Über-
leben belegt den Stellenwert von GO (3 mg/m2) in Kom-
bination mit Standard- und hoch dosiertem Cytarabin
und einem Anthrazyklin für die Induktion und Konsolidie-
rung bei neu diagnostizierter AML. Insbesondere Patien-
ten mit einem günstigen und intermediären zytogeneti-
schen Risikoprofil scheinen von der Gabe von GO zu pro-
fitieren. In der Behandlung von AML-Rezidiven oder re-
fraktärer Erkrankung erwies sich GO (3 mg/m2) als sicher
mit hoch dosiertem Cytarabin (3 g/m2) kombinierbar und
war in der Wirksamkeit historischen Vergleichskollekti-
ven der AMLSG-Studiengruppe überlegen. Erste Ergeb-
nisse dokumentieren die Möglichkeit einer allogenen
Stammzelltransplantation nach GO-Therapie. Erste Da-
ten einer laufenden Studie belegen auch die Einsatzmög-
lichkeit und das Sicherheitsprofil von GO als Bestandteil
einer Konditionierungstherapie von reduzierter Intensität
mit Fludarabin und Ganzkörperbestrahlung. 
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Summary
The value of the combination of gemtuzumab ozogam-
icin (GO) and chemotherapy for the treatment of acute
myeloid leukemia (AML) is currently analyzed within clin-
ical trials. GO (6 mg/m2) and standard-dose cytarabine
(100 mg/m2) is evaluated for the treatment of newly diag-
nosed AML in elderly patients in the SAL phase II trial.
Preliminary results of the MRC AML15 trial support the
application of GO 3 mg/m2 with standard- and high-dose
cytarabine and anthracyclines for the treatment of de
novo AML. Within this trial the addition of GO seems es-
pecially of value for favorable and intermediate cytoge-
netic risk groups. The combination of GO (3 mg/m2) and
high-dose cytarabine (3 g/m2) is safe and more effective
for the treatment of refractory AML than previous combi-
nations from the AMLSG study group. First results prove
the possibility of allogeneic stem cell transplantation
after GO therapy. Initial data of a phase II trial document
the safety and efficacy profile of GO within a reduced-in-
tensity conditioning protocol applying fludarabine and
total body irradiation.
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Introduction
Acute myeloid leukemia (AML) is the most frequent
leukemia in adults with an incidence of 3.7 in 100,000. Induc-
tion therapy with cytarabine (Ara-C) and an anthracycline
achieves a complete remission (CR) in 60–80% of the patients
[1–3]. However, recurrence occurs in the majority of the pa-
tients (50–80%). Salvage therapy is not standardized, and only
a median of 25% of patients enter a second CR lasting in most
cases 6–8 months [4–7]. 40–50% of the AML patients in 2nd
CR achieve a long-term survival after HLA-matched stem cell
transplantation (SCT) [8, 9]. However, not every patient qual-
ifies for this treatment approach [10].
After many attempts to improve results with conventional
combination chemotherapy, biological agents offer the possi-
bility of an increased response rate [11]. Such therapeutic op-
tions include gemtuzumab ozogamicin (GO), which is a hu-
manized monoclonal murine Ig4 antibody (hP67.6) targeting
the CD33 antigen. A bifunctional linker conjugates hP67.6
with the antibiotic calicheamicin, which is 1,000 times more
cytotoxic than doxorubin. After internalization of the antigen-
antibody complex, the low pH of the endosome induces hy-
drolysis of the linker. Calicheamicin binds sequence specific to
DNA, leading to DNA double-strand breaks and apoptosis.
GO is an attractive substance, as the CD33 glycoprotein is ex-
pressed on 90% of AML blasts. CD33 is also present on
myeloid precursor cells, macrophages, monocytes and dendrit-
ic cells, but not on hematopoietic stem cells, which are neces-
sary for hematopoietic repopulation [12–14].
Three multicenter phase II trials for relapsed AML were con-
ducted with 2 doses of GO 9 mg/m2 within 14 days in 277 pa-
tients and achieved 13% CR and 13% CR without complete
platelet recovery (CRp) [15, 16]. Clinically relevant toxicity
was bone marrow suppression and hepatopathy. GO is ap-
proved by the Food and Drug Administration (FDA) under
the name Mylotarg for monotherapy of relapsed AML in pa-
tients older than 60 years and is currently under review for ap-
proval at the European Medicines Agency (EMEA). Trials
are ongoing that analyze the toxicity profile and the efficacy of
GO with combination chemotherapy.
GO Chemotherapy for Relapsed or Refractory AML –
the AMLSG 05-04 Trial
In relapsed and refractory AML several combinations of GO
(4–9 mg/m2) with Ara-C (100 mg/m2) containing regimens
have been reported [17–22]. The AMLSG 05-04 trial com-
bines GO (3 mg/m2) with all-trans retinoic acid (ATRA, 45
mg/m2 day 4–6, 15 mg/m2 day 7–28), mitoxantrone (12 mg/m2
day 2, 3) and high-dose Ara-C (3 g/m2 day 1–3) (GO-A-
HAM) in patients < 60 years with refractory AML. The study
recruited up to now 76 patients (84 patients planned). In an in-
terim analysis, GO-A-HAM had similar treatment-related
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Fig. 2. Design of the MRC AML15 trial. After initial diagnosis patients
without an FLT mutation are randomized to a treatment with or without
gemtuzumab ozogamicin (GO) and 1. ADE 10+3+5: Ara-C (cytarabine)
100 mg/m2 twice daily day 1–10, daunorubicin 50 mg/m2 day 1, 3, 5, etopo-
side 100 mg/m2 day 1–5. The second course ADE 8+3+5: Ara-C 100
mg/m2 twice daily day 1–8, daunorubicin 50 mg/m2 day 1, 3, 5, etoposide
100 mg/m2 day 1–5 versus 2. DA 3+10: daunorubicin 50 mg/m2 day 1, 3, 5,
Ara-C 100 mg/m2 twice daily day 1–10. The second course of treatment is
DA 3+8: daunorubicin 50 mg/m2 day 1, 3, 5, Ara-C 100 mg/m2 twice daily
day 1–8 versus 3. FLAG-Ida: fludarabine 30 mg/m2 day 2–6, Ara-C 2 g/m2,
G-CSF day 1–7, idarubicin 8 mg/m2 day 4, 5, 6. Patients in complete re-
mission (CR) after induction therapy receive one course of consolidation
with or without GO and another consolidation course: 1. MACE:
amsacrine 100 mg/m2 day 1–5, Ara-C 200 mg/m2 day 1–5, etoposide 
100 mg/m2 day 1–5, followed by MidAc: mitoxantrone 10 mg/m2 day 1–5
and Ara-C 1 g/m2 day 1–3 versus 2. Ara-C 1.5 g/m2 day 1, 3, 5 versus 3.
Ara-C 3 g/m2 day 1, 3, 5.
Fig. 1. Design of the SAL phase II trial. The patients are randomized
after initial diagnosis to receive either treatment arm A (7+GO: GO 6
mg/m2, day 1; 4 mg/m2, day 8 and Ara-C 100 mg/m2 day 1–7, every 12 h)
or Arm B (7+3: dauno-rubicin 45 mg/m2 day 1–3 and Ara-C 100 mg/m2
day 1–7 every 12 h). In case of persisting leukemic blasts, patients change
to the 7+3 regimen. All patients in complete remission (CR) receive high-
dose Ara-C (HD Ara-C) for consolidation treatment. Patients with
persisting leukemia go off study. GO = gemtuzumab ozogamicin; Ara-C =
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Table 1. Gemtuzumab ozogamicin (GO) in combination with chemotherapy
GO dosage Chemotherapy Number of Complete Nonhematologic Reference
patients treated remission, % toxicity, %1
Relapsed AML
6 mg/m2 day 9 Ara-C, G-CSF 14 57 infections 23% [20]
6 mg/m2 day 1, 15 IA 14 42 sepsis 71% [17]
transaminitis 29%
9 mg/m2 day 1 Ara-C, topotecan 17 12 transaminitis 29% [19]
9 mg/m2 day 4 MA G-CSF 17 70 hyperbilirubinemia 24% [18]
infections 53%
4.5 mg/m2 day 1 CSA, fludarabin, Ara-C 32 34 hyperbilirubinemia 44% [22]
6 mg/m2 day 1 Ara-C 9 55 bleeding 33% [21]
4 mg/m2 day 8 sepsis 33%
transaminitis 33%
De novo AML
6 mg/m2 day 9 Ara-C, G-CSF 12 58 [20]
6 mg/m2 day 1 Ara-C 7 [31]
4 mg/m2 day 8
6 mg/m2 day1 Ara-C 24 36 [31]
3 mg/m2 day 1 H-DAT 22 91 hepatotoxicity 27% [28]
6 mg/m2 day 1 H-DAT 9 89 hepatotoxicity 56% [28]
3 mg/m2 day 1 DAT 10 60 hepatotoxicity 40% [28]
SOS 20%
early deaths 20%
3 mg/m2 day 1 DA 8 100 not given [28]
3 mg/m2 day 1 FLAG-Ida 15 87 hyperbilirubinemia 20% [28]
3 mg/m2 day 1 H-DAT 15 89 hepatotoxicity 33% [28]
SOS 33%
9 mg/m2 day 1, 8/15 ±IL11 15 µg/kg 51 36 [35]
4.5 mg/m2 day 1 CSA, fludarabine, Ara-C 22 neutropenic fever 23% [32]
6 mg/m2 day 1 CSA, fludarabine, Ara-C 59 48 pneumonia 38% [32]
FUO 38%
hyperbilirubinemia 31%
6 mg/m2 day 6 CSA, Ara-C, liposomal 11 18 sepsis 63% [27]
daunorubicin hyperbilirubinemia 54%
mucositis 27%
6 mg/m2 day 4 DA 53 83 mucositis 33% [33]
6 mg/m2 day 1/8 Ara-C 21 43 fever 29% [33]
chills 41%
9 mg/m2 day 1/15 40 infections 40% [26]
3 mg/m2 day 1 DAT, DA, or FLAG-Ida  18 [28]
followed by MACE
3 mg/m2 day 1 DAT, DA, or FLAG-Ida,  13 [28]
with HD Ara-C
3 mg/m2 day 1 DAT, DA, or FLAG-Ida, 23 [28]
course 1 and 3 with MACE or HD Ara-C 
GO 9 mg/m2 day 1/15 11 FUO 83% [29, 30]
of induction cardial 25%
GO 6 mg/m2 once day pulmonal 25%
45–60 for consolidation hypotension 25%
GO 3 mg/m2 once a month 
for maintenance
AML = Acute myeloid leukemia; SOS = sinusoidal obstruction syndrome; FUO = fever of unknown origin; HD Ara-C = high-dose Ara-C; Il 11 = inlerleukin 11; 
CSA = cyclosporin.
Ara-C, G-CSF: G-CSF 5 µg/kg, day 0–8; Ara-C (cytarabine) 100 mg/m2 day 4–8.
IA: Idarubicin 12 mg/m2 day 2–4; Ara-C 1.5 g/m2 day 2–5.
Ara-C, topotecan: Ara-C 1 g/m2 day 1–5, topotecan 1.25 mg/m2 day 1–5.
MA G-CSF: Ara-C 1 g/m2 /12 h day 1–5, mitoxantrone 12 mg/m2 day 1–3, G-CSF.
CSA, fludarabin, Ara-C: Fludarabin 15 mg/m2 day 2–6 (every 12 h), Ara-C 0.5 g/m2 day 2–6 (every 12 h), CSA 6 mg/kg day 1 + 16 mg/kg continuously iv day 1, 2.
Ara-C: Ara-C 100 mg/m2 day 1–7 continuously iv.
H-DAT: Daunorubicin day 1, 3, 5; Ara-C 200 mg/m2 day 1–10; thioguanine 2×/day, day 1–10.
DAT: Daunorubicin day 1, 3, 5; Ara-C 100 mg/m2 day 1–10; thioguanine 2×/day, day 1–10.
DA: Daunorubicin day 1, 3, 5; Ara-C 100 mg/m2 day 1–10.
FLAG-Ida: Fludarabine 30 mg/m2 day 2–6; Ara-C 2 g/m2, day 2–6; G-CSF, idarubicin 10 mg/m2 day 4–6.
CSA, Ara-C, liposomal daunorubicin: Ara-C 1 g/m2 day 1–5 (every 12 h), CSA 6 mg/kg day 6 + 16 mg/kg continuously iv day 6–8, liposomal daunorubicin 75 mg/m2 day 6–8.
MACE: Amsacrine 100 mg/m2 day 1–5, Ara-C 200 mg/m2 day 1–5, etoposide 100 mg/m2 day 1–5. 
1Nonhematologic toxicity grade III/IV occurring in more than 20% of the patients. 
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lethality as A-HAM (ATRA and HAM), S-HAM (sequential
high-dose Ara-C) or HAM (high-dose Ara-C). GO-A-HAM
induced a CR in 49% of patients, while A-HAM reached a
CR in 34%, S-HAM in 23%, and HAM in 24% of patients.
64% of patients with refractory AML responded to the GO-
A-HAM regimen (CR and PR). In a retrospective cohort
analysis, treatment with ATRA (p = 0.05) and GO (p = 0.05)
correlated with a good prognosis. Median survival after GO-
A-HAM accounted for 16.2 months (p = 0.002) as compared
to 12.5 months after A-HAM or 7.2 months after S-HAM or
HAM [23].
Randomized Trials for the Treatment of de novo AML –
the SAL Phase II Trial and the MRC AML15 Trial
As the addition of GO to standard chemotherapy 7+3 seemed
to be too toxic for elderly patients with AML, the randomized
SAL phase II trial compares 7+GO (GO 6 mg/m2, day 1; 4
mg/m2, day 8 and Ara-C 100 mg/m2 day 1–7, every 12 h) with
7+3 (daunorubicin 45 mg/m2 day 1–3 and Ara-C 100 mg/m2
day 1–7 every 12 h) for induction treatment of AML in pa-
tients > 60 years. The trial design provides consolidation with
Ara-C 1 g/m2 every 12 h day 1, 3, 5. This randomized trial has
recruited more than 50 patients so far. The trial is open for
participation within the German ‘Studien-Allianz Leukämien’
(SAL) (fig. 1). The combination of 7+GO may establish a less
cardiotoxic primary treatment for newly diagnosed AML in
elderly and frail patients, as far as both regimens reach equal
toxicity and efficacy. 
In patients of all age groups, the MRC AML15 trial analyzed
GO (3 mg/m2) for remission induction and consolidation (GO
6 mg/m2). This study is based on a 2 × 2 multifactorial design
providing different induction and consolidation treatments
with and without GO (fig. 2). So far more than 2,000 patients
are recruited into the trial. GO was combined in the induction
treatment with either ADE (Ara-C, daunorubicin, etoposide;
n = 160), DA (daunorubicin, Ara-C; n = 474) or FLAG-Ida
(fludarabine, Ara-C, G-CSF, idarubicin; n = 479) in 1,113 pa-
tients (median age: 49 years; cytogenetics: favorable 129, in-
termediate 631, adverse 132) [24]. No increased liver toxicity
was observed after GO therapy; similar recovery times were
observed for neutrophils (20 days) and platelets (20 days vs 18
days) with and without GO. Similar CR rates were achieved
with and without GO (84% with GO vs 86% without GO). In-
terestingly, at a median follow-up of 16 months in 964 patients,
GO led to fewer relapses (37% vs 52% at 3 years, p = 0.01),
resulting in a significantly improved disease-free survival
(51% vs 40%, p = 0.008) of the patients with de novo AML.
No extra liver toxicity was seen in subsequent stem cell trans-
plantations. 
GO and Stem Cell Transplantation 
Several trials confirmed feasibility of allogeneic SCT in GO-
treated patients. After a GO-containing regimen, CR/CRp pa-
tients reached a median survival of > 18.3 months (n = 14)
with allogeneic SCT, 16.5 months (n = 11) with autologous
SCT, 12.2 months with additional chemotherapy (n = 11), and
11.2 months without further treatment (n = 35; p = 0.007) [16].
The German Study Initiative on Leukemias conducted a
phase II trial in relapsed AML with reduced-intensity condi-
tioning therapy. So far, results of 19 patients are available that
have been treated with GO (GO 6 mg/m2 day –21 and GO 3
mg/m2 day –14), fludarabine (30 mg/m2 day –3 up to day –1),
and total body irradiation (TBI; 800 or 200 cGY depending on
the relapse-free interval and age), followed by allogeneic SCT
in aplasia. After TBI, 75% of patients reached a CR. Seven
patients are alive and in CR. With a median follow-up of 21
months no sinusoidal obstruction syndrome (SOS) and de-
layed liver toxicity was documented. The probability of over-




The toxicity profile allows the application of GO together
with chemotherapy (table 1) [20, 26–32]. GO in combination
with intensive induction or consolidation therapy was initially
analyzed by Kell et al. [28, 33]. GO 3 mg/m2 proved applicable
for induction therapy with daunorubicin and Ara-C or FLAG-
Ida as well as MACE (amsacrine, Ara-C, etoposide) or high-
dose Ara-C [28]. In the MRC AML15 trial GO (3 mg/m2) re-
duced the risk of relapse in de novo AML and improved dis-
ease-free survival without additional toxicity. Preliminary data
indicate that favorable and intermediate cytogenetic risk
groups may particularly benefit from addition of GO. Ran-
domized comparisons of GO and Fms-like tyrosine kinase 3
(FLT-3) inhibitors are ongoing in patients with FLT-3 muta-
tions. Results of the randomized German SAL phase II trial
are awaited, that analyzes in elderly patients the substitution
of daunorubicin by GO in a setting with standard-dose Ara-C
(100 mg/m2 for 5–7 days).
Relapsed and Refractory AML
Single-agent GO therapy (9 mg/m2) is approved for the treat-
ment of relapsed AML. Application of GO (3–9 mg/m2) and
chemotherapy (Ara-C 100 mg/m2–1 g/m2) achieved CR rates
of 12–70% and a median overall survival of 2–11 months in re-
fractory or relapsed AML (table 1) [17–22]. In line with these
results are the data of the AMLSG trial that favor the GO-A-
HAM (GO 3 mg/m2) regimen in comparison to other modifi-
cations of high-dose Ara-C-containing protocols. Randomized
trials are outstanding and data are preliminary.




The results of Larson et al. confirm feasibility of SCT and GO
for the treatment of AML in first relapse [16]. In the context
of myeloablative conditioning chemotherapy, SOS developed
in 5/27 (19%) patients transplanted prior to GO. SOS 
occurred in 8/40 (17%) patients transplanted after GO. GO 
2 mg/m2 was applicable with fludarabine/melphalan before al-
logeneic SCT [34]. The ongoing German trial supports incor-
poration of GO in a reduced-intensity conditioning regimen
with fludarabine and TBI exploiting the aplastic potential of
GO within this indication.
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